Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 August 2024 | Story Mbali Moiketsi
Alexander Solomons
EMS honours student Alexander Solomons has been awarded the 2024/2025 Ernst Mach Grant to take part in an exchange programme with FH Salzburg University.

Alexander Solomons, an honours student in the Faculty of Economic and Management Sciences at the University of the Free State (UFS), has been awarded the prestigious Ernst Mach Grant for the 2024/2025 academic year. This competitive grant will enable Solomons to participate in an exchange programme at FH Salzburg University, one of Europe’s leading institutions for higher education and research, in Salzburg, Austria.

The Ernst Mach Grant, named after the renowned physicist and philosopher Ernst Mach, is funded by the Austrian Federal Ministry of Education, Science, and Research. It aims to foster international academic exchange and support students who demonstrate exceptional academic merit and a strong commitment to their field of study.

“Spending time abroad did not seem like something that I would be able to do so early in my life,” Solomons said. “Coming from Scottsville, Kraaifontein, in the Western Cape, I never thought that I would be able to take part in opportunities such as this one.”

“Alexander’s selection as an Ernst Mach Grant recipient is a testament to his hard work, dedication, and the high standards of academic programmes at the UFS,” said Lynette Jacobs, Acting Director in the Office for International Affairs at the UFS.

During his time at FH Salzburg University, Solomons will have the opportunity to immerse himself in a vibrant academic environment, engage with leading scholars in his field, and access cutting-edge resources and facilities. “I will have the opportunity to deepen my knowledge and engage in a different form of high-impact learning,” he said. “Professionally, international experience can be valuable in the advancement of my career. Being exposed to global practices as well as networking has the potential to enhance my career prospects and potentially open doors for me in the country I originate from and internationally.”

Jacobs added that this programme will not only enhance Solomons’ academic and professional development but also strengthen the international ties between the UFS and FH Salzburg University.

"I am thrilled to witness the incredible opportunities scholarship programmes offer to our students,” she said. “Scholarships like the Ernst Mach Grant not only provide financial support but also open doors to unparalleled academic and cultural experiences. I strongly encourage all UFS students to explore these opportunities and apply for scholarships. Studying abroad can be a life-changing experience, offering new perspectives, fostering personal growth, and building a global network.”

In addition to his academic pursuits, Solomons will serve as an ambassador for the UFS, sharing his experiences and insights with his peers and faculty members at FH Salzburg University. He intends to integrate the knowledge gained into research and projects he takes on in the future. He believes the exposure to diverse opinions can help him approach problems from a more global perspective, and help him think in a more adaptable and inclusive manner.

“His participation in this exchange programme will contribute to the ongoing efforts to promote international collaboration and cultural exchange within our academic community,” Jacobs said.

Students and staff interested in applying for scholarships are welcome to contact Mbali Moiketsi, Study Abroad Officer  in the Office for International Affairs on the top floor of the Theology Building.  Information about scholarships is shared regularly through channels such as newsletters, social media, and the UFS website.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept